The deal gives Xellia capacity in North America for the first time, providing the company with a platform from which to realize the mid-term growth opportunities envisaged by Novo A/S when it bought the company.
So far, 2014 hasn't been the best year for Denmark's Novo Nordisk. The perenially fast-growing drugmaker saw sales growth slip into the single digits for the first quarter.
U.S. diabetes patients are much more likely to use a vial and syringe than Europeans, who prefer a prefilled pen. Diabetes powerhouse Novo Nordisk is looking to remedy that situation with the introduction of a new, easier-to-use pen onto the U.S. market: the Levemir FlexTouch.
Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.
Combine the blockbuster GLP-1 drug Victoza with a long-acting insulin and you get a treatment greater than the sum of its parts, according to Novo Nordisk, which unveiled promising new data on its diabetes cocktail IDegLira.
Novo Nordisk has been staffing up its sales and marketing teams in the U.S. at a time when bigger rivals are cutting back. Turns out, the Danish drugmaker has big plans for expansion back home as well.
While Victoza brought in more than $2 billion last year, it has been dogged by concerns that it raises the risk of pancreatitis--and despite it and other similar drugs being cleared by reviews by both the FDA and EU regulators this year, some keep pushing the FDA to consider pulling it off the market.
Novo Nordisk has decided to play ball in Germany. The Danish drugmaker now plans to launch its brand-new diabetes drug Tresiba in that country, despite a notorious pricing policy that Novo feared would interfere with its success.
With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.
Novo Nordisk has a date with an FDA advisory panel. The subject: Its blockbuster diabetes drug liraglutide, which it's hoping to rebrand into an obesity treatment. What could follow: Big sales from a bigger market.